» Articles » PMID: 10793068

P16(INK4a) Gene Alterations Are Frequent in Lesions of Mycosis Fungoides

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2000 May 4
PMID 10793068
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Mycosis fungoides is usually an indolent disease that, after a variable period of time in a stable phase, evolves into a tumoral form with aggressive behavior. The molecular events that mark this progression remain essentially unknown to date, and this prompted us to investigate the hypothetical role of p16(INK4a) silencing in mycosis fungoides progression. We analyzed the three most frequent mechanisms of inactivation of the p16(INK4a) gene (deletion, promoter hypermethylation, and mutation) in nine cases with patch/plaque and tumoral lesions of mycosis fungoides. The existence of alterations was investigated by microsatellite analysis, methylation-specific polymerase chain reaction, and direct sequencing. Alterations of the p16(INK4a) gene were found in four of nine of the plaque lesions (hypermethylation in three samples and allelic loss in one sample) and seven of nine in the tumor lesions (hypermethylation in five samples and allelic loss in three samples). No case presented point mutations. Although a higher incidence of p16(INK4a) hypermethylation was observed in the cases that failed to achieve a complete remission, the limited size of our series prompted us to evaluate this finding cautiously. The results of this study therefore showed a common genetic alteration that is found more frequently in tumoral lesions than it is in plaque lesions of mycosis fungoides. It also offers data that could suggest a relationship between p16(INK4a) hypermethylation and unfavorable clinical outcome. Broader studies are needed to confirm both relationships.

Citing Articles

Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.

Vitiello P, Sagnelli C, Ronchi A, Franco R, Caccavale S, Mottola M Healthcare (Basel). 2023; 11(4).

PMID: 36833148 PMC: 9957453. DOI: 10.3390/healthcare11040614.


Epigenetics of Cutaneous T-Cell Lymphomas.

Hara N, Sawada Y Int J Mol Sci. 2022; 23(7).

PMID: 35408897 PMC: 8998216. DOI: 10.3390/ijms23073538.


Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides.

Di Raimondo C, Han Z, Su C, Wu X, Qin H, Sanchez J Cancers (Basel). 2021; 13(22).

PMID: 34831008 PMC: 8616450. DOI: 10.3390/cancers13225854.


Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.

Lai P, Wang Y Cancer Biol Med. 2021; 18(1):34-51.

PMID: 33628583 PMC: 7877166. DOI: 10.20892/j.issn.2095-3941.2020.0216.


Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population.

Sherman S, Kremer N, Dalal A, Solomon-Cohen E, Berkovich E, Noyman Y Acta Derm Venereol. 2020; 100(19):adv00346.

PMID: 33241425 PMC: 9309703. DOI: 10.2340/00015555-3704.


References
1.
Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K . Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood. 1995; 86(4):1548-56. View

2.
Garatti S, Roscetti E, Trecca D, Fracchiolla N, Neri A, Berti E . bcl-1, bcl-2, p53, c-myc, and lyt-10 analysis in cutaneous lymphomas. Recent Results Cancer Res. 1995; 139:249-61. DOI: 10.1007/978-3-642-78771-3_19. View

3.
Herman J, Merlo A, Mao L, Lapidus R, Issa J, Davidson N . Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55(20):4525-30. View

4.
Gonzalez-Zulueta M, Bender C, Yang A, Nguyen T, Beart R, Van Tornout J . Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995; 55(20):4531-5. View

5.
Cairns P, Polascik T, Eby Y, Tokino K, Califano J, Merlo A . Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995; 11(2):210-2. DOI: 10.1038/ng1095-210. View